Vistin Pharma ASA (OSL:VISTN)
Norway · Delayed Price · Currency is NOK | Market Cap | 909.06M -17.3% |
| Revenue (ttm) | 449.47M +2.0% |
| Net Income | 74.55M -2.9% |
| EPS | 1.68 -3.0% |
| Shares Out | 44.34M |
| PE Ratio | 12.20 |
| Forward PE | n/a |
| Dividend | 1.50 (7.25%) |
| Ex-Dividend Date | May 22, 2026 |
| Volume | 10,605 |
| Open | 20.70 |
| Previous Close | 20.70 |
| Day's Range | 20.50 - 20.90 |
| 52-Week Range | 19.40 - 26.30 |
| Beta | 0.62 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 20, 2026 |
About Vistin Pharma ASA
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; metformin direct compressible; and metformin premixed with lubricant magnesium stearate for use in plain metformin immediate release tablets. The company was founded in 1969 and is based in Oslo, Norway. [Read more]
Full Company ProfileFinancial Performance
In 2025, Vistin Pharma ASA's revenue was 452.29 million, an increase of 5.31% compared to the previous year's 429.50 million. Earnings were 74.75 million, an increase of 19.13%.
Financial StatementsNews
Vistin Pharma ASA Slides: Redeye Theme Event Diabetes presentation
Vistin Pharma ASA has posted slides in relation to its latest quarterly earnings report, which was published on May 6, 2026.
Vistin Pharma ASA Earnings Call Transcript: Q1 2026
Q1 2026 saw stable revenue and profit, with strong sales volume offset by currency and price pressures. Safety stock and a renewable energy deal mitigate supply risks, while a planned Q4 maintenance stop will temporarily impact output. Dividend of up to NOK 1.5/share proposed.
Vistin Pharma ASA Quarterly report: Q1 2026
Vistin Pharma ASA has published its Q1 2026 quarterly earnings report on April 24, 2026.
Vistin Pharma ASA Slides: Q1 2026
Vistin Pharma ASA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 24, 2026.
Vistin Pharma ASA Slides: DNB Carnegie Nordic SMB Conference presentation
Vistin Pharma ASA has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.
Vistin Pharma ASA Earnings Call Transcript: Q4 2025
Q4 2025 saw record sales volume and a 5% revenue increase for the year, but lower metformin prices led to a Q4 revenue decline. Full-year EBITDA and net profit reached all-time highs, with strong margins and a proposed NOK 1.5 per share dividend.
Vistin Pharma ASA Quarterly report: Q4 2025
Vistin Pharma ASA has published its Q4 2025 quarterly earnings report on February 12, 2026.
Vistin Pharma ASA Slides: Q4 2025
Vistin Pharma ASA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.
Vistin Pharma ASA Annual report: Q4 2025
Vistin Pharma ASA has published its Q4 2025 annual report on February 12, 2026.
Vistin Pharma ASA Earnings Call Transcript: Q3 2025
Q3 2025 saw 3% revenue growth and a 10% sales volume increase, with EBITDA at NOK 28 million and net profit up year-over-year. Production hit a record 1,600 metric tons, and the company remains focused on ramping capacity and maintaining strong margins amid stable demand and favorable market trends.
Vistin Pharma ASA Quarterly report: Q3 2025
Vistin Pharma ASA has published its Q3 2025 quarterly earnings report on October 31, 2025.
Vistin Pharma ASA Slides: Q3 2025
Vistin Pharma ASA has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 31, 2025.
Vistin Pharma ASA Earnings Call Transcript: Q2 2025
Q2 2025 saw 11% revenue and EBITDA growth, driven by record sales volumes and strong gross margins. Market demand for metformin remains robust, with ongoing capacity expansion and stable operational performance.
Vistin Pharma ASA Quarterly report: Q2 2025
Vistin Pharma ASA has published its Q2 2025 quarterly earnings report on August 15, 2025.
Vistin Pharma ASA Slides: Q2 2025
Vistin Pharma ASA has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 15, 2025.